Objective To investigate the effectiveness and safety of drug-eluting beads bronchial arterial chemoembolization(DEB-BACE)versus BACE for the treatment of stage Ⅲ-Ⅳ lung squamous cell carcinoma.Methods A total of 104 patients with stage Ⅲ-Ⅳ lung squamous cell carcinoma,who were admitted to the Lishui Municipal Central Hospital of China between January 2013 and August 2021,were enrolled in this study.According to the therapeutic scheme,the patients were divided into DEB-BACE group(n=41)and BACE group(n=63).For patients of DEB-BACE group,Cisplatin at 75 mg/m2 dose and gemcitabine at 1 000 mg/m2 dose(400 mg was used as loaded-drug dose)were injected through a microcatheter,which was followed by embolization with CalliSpheres microspheres loaded with 400 mg of gemcitabine.For patients of BACE group,Cisplatin at 75 mg/m2 and gemcitabatin at 1 000 mg/m2 were injected through a microcatheter,which was followed by arterial embolization with blank microspheres.Three weeks after DEB-BACE or BACE,the patients of both groups were started on intravenous chemotherapy.The primary study endpoint was overall survival(OS).The secondary study endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),adverse reactions,and the remission rate of dyspnea.Results Of the 104 patients,63 received BACE sequential intravenous chemotherapy and 41 received DEB-BACE sequential intravenous chemotherapy.The median OS in DEB-BACE group was 23.0 moths,which was obviously longer than 12.0 months in BACE group(P=0.009).Multivariate Cox regression analysis showed that DEB-BACE treatment was an independent risk factor for OS(HR=0.59,95％ CI:0.38-0.91,Log-rank test P=0.018).Meanwhile,the remission rate of dyspnea in DEB-BACE group was significantly higher than that in BACE group(57.1％ vs 30.6％,P＜0.043).Conclusion Compared with BACE sequential intravenous chemotherapy,DEB-BACE sequential intravenous chemotherapy can significantly prolong the survival time of patients with stage Ⅲ-Ⅳ lung squamous cell carcinoma and significantly improve the symptoms of dyspnea,which has important applications in the treatment of patients with advanced lung squamous cell carcinoma.

Objective To explore the influence of the treatment and T-cell subsets in patients with recurrent genital herpes (RGH) by two treatment methods. Methods 64 cases of RGH patients were randomly divided int0 2 groups: 32 patients in the unite treatment group, the control group of 32 patients. Control group oral valaciclovir. The unite treatment group of oral valaciclovir tablets, in addition, also accepted mycobacterium phle injection treatment. All the patients before and after treatment were analyzed by flow cytometry using T-cell subsets. Results In the unite treatment group after treatment RGH relapse frequency [(1.01±0.79)] than that of the control group [(2.53±0.93)] was significantly decreased (P<0.001). In the unite treatment group after treatment CD+4 T cells and CDCD+4/CDCD+8 ratio than the control group were significantly increased (P<0.05), CD+8 cells compared with the control group was significantly decreased (P<0.05). Conclusion The cellular immunity is abnormal in RGH patients and it plays an important role in pathogenesis of RGH. Mycobacterium phle may enhance cellular immunity of the patients and these patients treated with it showed some better effects.

Objective To investigate the lymphocyte subsets,natural killer(NK) and soluble interleukin-2 receptors(SIL-2R) in syphilis patients with negative HIV and evaluate its clinical significance.Methods T-lymphocyte subsets,NK lymphocyte and SIL-2R were measured with flowcytometry(FCM) and enzyme linked immuno-sorbent assay(ELISA) from 60 cases of untreated group(28 cases),treated group(32 cases) and controls group(30 cases) in patients with latent syphilis.Results The percentage of CD_8 in untreated group(0.33?0.08) was markedly higher than controls group(0.25?0.04)(P